FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1989479329> ?p ?o ?g. }

• W1989479329 endingPage "1661" @default.
• W1989479329 startingPage "1653" @default.
• W1989479329 abstract "Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.BackgroundIn chronic renal failure (CRF), hyperphosphatemia and an elevated calcium-phosphate product are associated with vascular calcification and increased cardiovascular morbidity and mortality. Previous data have demonstrated that 3-month treatment of uremic rats with sevelamer was associated with less nephrocalcinosis compared to calcium carbonate (CaCO3), despite similar control of serum phosphorus, calcium-phosphorus product (Ca x P product), and secondary hyperparathyroidism. There was no evidence of aortic calcification after 3 months of uremia (J Am Soc Nephrol 13:2299–2308, 2002). The present studies explore the influence of sevelamer and CaCO3 on cardiovascular and kidney calcifications in long-term experimental uremia over 6 months.MethodsNormal and 5/6 nephrectomized rats (U) were fed a high phosphorus (HP) diet for 6 months. Two phosphate binders, CaCO3 and sevelamer, were administered and their influence on hyperphosphatemia, secondary hyperparathyroidism, kidney/myocardial/aortic calcification, and renal function was compared.ResultsAll uremic rats began the study with the same degree of renal failure. Sevelamer was as effective as CaCO3 in reducing serum phosphorus, Ca x P product, and attenuating secondary hyperparathyroidism. Despite similar serum cholesterol levels, rats in the U-HP + sevelamer group had markedly lower calcium deposition in the myocardium and aorta (myocardium, 72 ± 4 μg/g wet tissue; aorta, 736 ± 156 μg/g wet tissue) compared to rats in either the U-HP + CaCO3 group (myocardium, 179 ± 48, P < 0.05; aorta, 1308 ± 343, P < 0.05) or the U-HP group (myocardium, 98 ± 10, NS; aorta, 2150 ± 447, P < 0.05). Dual immunohistochemical analysis for calcium and endothelial cell markers demonstrated that myocardial calcium deposition was intravascular within capillaries. Furthermore, calcium deposition in the kidney of uremic rats treated with sevelamer (582 ± 111 μg/g wet tissue) was lower than that found in uremic rats treated with CaCO3 (1196 ± 180 μg/g wet tissue). Sevelamer-treated rats had less deterioration in renal function with an associated lower serum creatinine, higher creatinine clearance, and less proteinuria. There was no difference in overall mortality between the three experimental groups.ConclusionIn long-term experimental CRF, in addition to controlling serum phosphorus and secondary hyperparathyroidism as efficiently as CaCO3, treatment with the phosphate-binder sevelamer attenuates vascular and kidney calcification. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. In chronic renal failure (CRF), hyperphosphatemia and an elevated calcium-phosphate product are associated with vascular calcification and increased cardiovascular morbidity and mortality. Previous data have demonstrated that 3-month treatment of uremic rats with sevelamer was associated with less nephrocalcinosis compared to calcium carbonate (CaCO3), despite similar control of serum phosphorus, calcium-phosphorus product (Ca x P product), and secondary hyperparathyroidism. There was no evidence of aortic calcification after 3 months of uremia (J Am Soc Nephrol 13:2299–2308, 2002). The present studies explore the influence of sevelamer and CaCO3 on cardiovascular and kidney calcifications in long-term experimental uremia over 6 months. Normal and 5/6 nephrectomized rats (U) were fed a high phosphorus (HP) diet for 6 months. Two phosphate binders, CaCO3 and sevelamer, were administered and their influence on hyperphosphatemia, secondary hyperparathyroidism, kidney/myocardial/aortic calcification, and renal function was compared. All uremic rats began the study with the same degree of renal failure. Sevelamer was as effective as CaCO3 in reducing serum phosphorus, Ca x P product, and attenuating secondary hyperparathyroidism. Despite similar serum cholesterol levels, rats in the U-HP + sevelamer group had markedly lower calcium deposition in the myocardium and aorta (myocardium, 72 ± 4 μg/g wet tissue; aorta, 736 ± 156 μg/g wet tissue) compared to rats in either the U-HP + CaCO3 group (myocardium, 179 ± 48, P < 0.05; aorta, 1308 ± 343, P < 0.05) or the U-HP group (myocardium, 98 ± 10, NS; aorta, 2150 ± 447, P < 0.05). Dual immunohistochemical analysis for calcium and endothelial cell markers demonstrated that myocardial calcium deposition was intravascular within capillaries. Furthermore, calcium deposition in the kidney of uremic rats treated with sevelamer (582 ± 111 μg/g wet tissue) was lower than that found in uremic rats treated with CaCO3 (1196 ± 180 μg/g wet tissue). Sevelamer-treated rats had less deterioration in renal function with an associated lower serum creatinine, higher creatinine clearance, and less proteinuria. There was no difference in overall mortality between the three experimental groups. In long-term experimental CRF, in addition to controlling serum phosphorus and secondary hyperparathyroidism as efficiently as CaCO3, treatment with the phosphate-binder sevelamer attenuates vascular and kidney calcification." @default.
• W1989479329 created "2016-06-24" @default.
• W1989479329 creator A5003294187 @default.
• W1989479329 creator A5008053180 @default.
• W1989479329 creator A5016639035 @default.
• W1989479329 creator A5026687686 @default.
• W1989479329 creator A5047048608 @default.
• W1989479329 creator A5059200158 @default.
• W1989479329 creator A5070573262 @default.
• W1989479329 date "2003-11-01" @default.
• W1989479329 modified "2023-10-13" @default.
• W1989479329 title "Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia" @default.
• W1989479329 cites W1967933104 @default.
• W1989479329 cites W1973653270 @default.
• W1989479329 cites W1977303973 @default.
• W1989479329 cites W1986695347 @default.
• W1989479329 cites W1992951332 @default.
• W1989479329 cites W1994057975 @default.
• W1989479329 cites W1997509479 @default.
• W1989479329 cites W2008678562 @default.
• W1989479329 cites W2030174339 @default.
• W1989479329 cites W2031378939 @default.
• W1989479329 cites W2037687164 @default.
• W1989479329 cites W2039657743 @default.
• W1989479329 cites W2045847718 @default.
• W1989479329 cites W2075394310 @default.
• W1989479329 cites W2095628817 @default.
• W1989479329 cites W2101385628 @default.
• W1989479329 cites W2106275671 @default.
• W1989479329 cites W2110693651 @default.
• W1989479329 cites W2123780246 @default.
• W1989479329 cites W2129352623 @default.
• W1989479329 cites W2134132325 @default.
• W1989479329 cites W2143600593 @default.
• W1989479329 cites W2144652526 @default.
• W1989479329 cites W2157770824 @default.
• W1989479329 cites W2328615536 @default.
• W1989479329 cites W4239389810 @default.
• W1989479329 doi "https://doi.org/10.1046/j.1523-1755.2003.00284.x" @default.
• W1989479329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14531797" @default.
• W1989479329 hasPublicationYear "2003" @default.
• W1989479329 type Work @default.
• W1989479329 sameAs 1989479329 @default.
• W1989479329 citedByCount "133" @default.
• W1989479329 countsByYear W19894793292012 @default.
• W1989479329 countsByYear W19894793292013 @default.
• W1989479329 countsByYear W19894793292014 @default.
• W1989479329 countsByYear W19894793292015 @default.
• W1989479329 countsByYear W19894793292016 @default.
• W1989479329 countsByYear W19894793292017 @default.
• W1989479329 countsByYear W19894793292018 @default.
• W1989479329 countsByYear W19894793292019 @default.
• W1989479329 countsByYear W19894793292020 @default.
• W1989479329 countsByYear W19894793292021 @default.
• W1989479329 countsByYear W19894793292022 @default.
• W1989479329 crossrefType "journal-article" @default.
• W1989479329 hasAuthorship W1989479329A5003294187 @default.
• W1989479329 hasAuthorship W1989479329A5008053180 @default.
• W1989479329 hasAuthorship W1989479329A5016639035 @default.
• W1989479329 hasAuthorship W1989479329A5026687686 @default.
• W1989479329 hasAuthorship W1989479329A5047048608 @default.
• W1989479329 hasAuthorship W1989479329A5059200158 @default.
• W1989479329 hasAuthorship W1989479329A5070573262 @default.
• W1989479329 hasBestOaLocation W19894793291 @default.
• W1989479329 hasConcept C126322002 @default.
• W1989479329 hasConcept C134018914 @default.
• W1989479329 hasConcept C2775945674 @default.
• W1989479329 hasConcept C2776036575 @default.
• W1989479329 hasConcept C2776635150 @default.
• W1989479329 hasConcept C2777425297 @default.
• W1989479329 hasConcept C2778063415 @default.
• W1989479329 hasConcept C2778653478 @default.
• W1989479329 hasConcept C2778838027 @default.
• W1989479329 hasConcept C2779148903 @default.
• W1989479329 hasConcept C2780091579 @default.
• W1989479329 hasConcept C2780309369 @default.
• W1989479329 hasConcept C2781208988 @default.
• W1989479329 hasConcept C519063684 @default.
• W1989479329 hasConcept C71924100 @default.
• W1989479329 hasConceptScore W1989479329C126322002 @default.
• W1989479329 hasConceptScore W1989479329C134018914 @default.
• W1989479329 hasConceptScore W1989479329C2775945674 @default.
• W1989479329 hasConceptScore W1989479329C2776036575 @default.
• W1989479329 hasConceptScore W1989479329C2776635150 @default.
• W1989479329 hasConceptScore W1989479329C2777425297 @default.
• W1989479329 hasConceptScore W1989479329C2778063415 @default.
• W1989479329 hasConceptScore W1989479329C2778653478 @default.
• W1989479329 hasConceptScore W1989479329C2778838027 @default.
• W1989479329 hasConceptScore W1989479329C2779148903 @default.
• W1989479329 hasConceptScore W1989479329C2780091579 @default.
• W1989479329 hasConceptScore W1989479329C2780309369 @default.
• W1989479329 hasConceptScore W1989479329C2781208988 @default.
• W1989479329 hasConceptScore W1989479329C519063684 @default.
• W1989479329 hasConceptScore W1989479329C71924100 @default.
• W1989479329 hasIssue "5" @default.
• W1989479329 hasLocation W19894793291 @default.
• W1989479329 hasLocation W19894793292 @default.
• W1989479329 hasOpenAccess W1989479329 @default.

• next